The partnership will build on previous collaborations made by both companies
Be The Match BioTherapies and Lonza have announced a strategic partnership for cell and gene therapy. The collaboration’s goal is to improve efficiency across the CGT supply chain, targeting of apheresis network management, healthy donor tissue supply, manufacturing and, where appropriate, supply chain management and logistics.
The partnership is aimed at supporting the companies' shared goal of providing end-to-end solutions that streamline development across the CGT supply chain. Lonza and Be The Match BioTherapies will integrate each other's services in their respective offerings.
This collaboration builds on partnerships announced by the companies to build a larger network for customers and their patients. Partners of Lonza include Cryoport, a leading temperature-controlled supply chain company, and Vineti, a company developing a commercial, configurable, cloud-based digital platform to orchestrate advanced therapy supply chains. Be The Match BioTherapies has reportedly delivered more than 100,000 cell therapies, and brings expertise in logistics, managing apheresis networks, and the ability to provide high-quality cellular source material from its registry of more than 22 million potential blood and marrow donors.
Alberto Santagostino, SVP, Head of Cell and Gene Therapy, Lonza said: "Be The Match BioTherapies brings deep experience in overcoming supply chain and logistical challenges impacting developers of cell and gene therapies, including factors that delay patients' ability to access the treatments they need. We're pleased to add their team to our growing network of strategic partners and look forward to working together to cultivate a more seamless, streamlined ecosystem for cell and gene therapy development."
Chris McClain, MBA, SVP, Sales and New Business Development, Be The Match BioTherapies said: "Lonza plays a central role in Be The Match BioTherapies' pursuit of accelerating patient access to high-quality manufactured cell therapies. This collaboration will allow our teams to combine our substantial expertise and resources across the cell therapy supply chain to ease the logistical burden for cell and gene therapy developers globally. By offering the ability to leverage a fully integrated cell and gene therapy supply chain, we can ultimately provide a brighter future for patients."